All In Biotech

Drug Trial Radar · NCT05775523

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

Last checked: Nov 20, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Mar 20, 2023

Primary completion

Mar 2033

Study completion Mar 2033

Sponsor

Sponsor type
Industry
First posted
Mar 20, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.

Conditions

  • Growth Hormone Deficiency

Interventions

  • No interventionDrug

    No intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of neoplasms (benign, malignant and unspecified)Time frame: 5 years
  2. Occurrence of type 2 diabetes mellitusTime frame: 5 years

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Ascendis Investigational Site

    Phoenix, Arizona · Recruiting

  • Ascendis Investigational Site

    Orange, California · Recruiting

  • Ascendis Investigational Site

    Sacramento, California · Recruiting

  • Ascendis Investigational Site

    San Francisco, California · Recruiting

  • Ascendis Pharma Investigational Site

    Centennial, Colorado · Recruiting

  • Ascendis Investigational Site

    Washington D.C., District of Columbia · Recruiting

  • Ascendis Investigational Site

    Orlando, Florida · Recruiting

  • Ascendis Investigational Site

    Orlando, Florida · Recruiting

  • Ascendis Investigational Site

    Tampa, Florida · Recruiting

  • Ascendis Investigational Site

    Sandy Springs, Georgia · Recruiting

  • Ascendis Investigational Site

    Boise, Idaho · Recruiting

  • Ascendis Investigational Site

    Indianapolis, Indiana · Recruiting

  • Ascendis Investigational Site

    Iowa City, Iowa · Recruiting

  • Ascendis Investigational Site

    Louisville, Kentucky · Recruiting

  • Ascendis Investigational Site

    Minneapolis, Minnesota · Recruiting

  • Ascendis Investigational Site

    Las Vegas, Nevada · Recruiting

  • Ascendis Investigational Site

    Lebanon, New Hampshire · Recruiting

  • Ascendis Investigational Site

    Manchester, New Hampshire · Recruiting

  • Ascendis Investigational Site

    Morristown, New Jersey · Recruiting

  • Ascendis Investigational Site

    New Hyde Park, New York · Recruiting

  • Ascendis Investigational Site

    Cincinnati, Ohio · Recruiting

  • Ascendis Investigational Site

    Portland, Oregon · Recruiting

  • Ascendis Investigational Site

    Columbia, South Carolina · Recruiting

  • Ascendis Investigational Site

    Dallas, Texas · Recruiting

  • Ascendis Investigational Site

    El Paso, Texas · Recruiting

  • Ascendis Investigational Site

    Norfolk, Virginia · Recruiting

  • Ascendis Investigational Site

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.